These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 21289076

  • 1. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations.
    Filppula AM, Laitila J, Neuvonen PJ, Backman JT.
    Drug Metab Dispos; 2011 May; 39(5):904-11. PubMed ID: 21289076
    [Abstract] [Full Text] [Related]

  • 2. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.
    Muschler E, Lal J, Jetter A, Rattay A, Zanger U, Zadoyan G, Fuhr U, Kirchheiner J.
    Basic Clin Pharmacol Toxicol; 2009 Dec; 105(6):374-9. PubMed ID: 19614891
    [Abstract] [Full Text] [Related]

  • 3. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.
    Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT.
    Clin Pharmacol Ther; 2010 Aug; 88(2):223-30. PubMed ID: 20592724
    [Abstract] [Full Text] [Related]

  • 4. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
    Chang SY, Li W, Traeger SC, Wang B, Cui D, Zhang H, Wen B, Rodrigues AD.
    Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
    [Abstract] [Full Text] [Related]

  • 5. Selective inhibition of human cytochrome P4502C8 by montelukast.
    Walsky RL, Obach RS, Gaman EA, Gleeson JP, Proctor WR.
    Drug Metab Dispos; 2005 Mar; 33(3):413-8. PubMed ID: 15608135
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate.
    VandenBrink BM, Foti RS, Rock DA, Wienkers LC, Wahlstrom JL.
    Drug Metab Dispos; 2011 Sep; 39(9):1546-54. PubMed ID: 21697463
    [Abstract] [Full Text] [Related]

  • 7. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans.
    Chiba M, Xu X, Nishime JA, Balani SK, Lin JH.
    Drug Metab Dispos; 1997 Sep; 25(9):1022-31. PubMed ID: 9311616
    [Abstract] [Full Text] [Related]

  • 8. Characterization of metabolites and human P450 isoforms involved in the microsomal metabolism of mesaconitine.
    Ye L, Tang L, Gong Y, Lv C, Zheng Z, Jiang Z, Liu Z.
    Xenobiotica; 2011 Jan; 41(1):46-58. PubMed ID: 21105783
    [Abstract] [Full Text] [Related]

  • 9. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
    Jaakkola T, Laitila J, Neuvonen PJ, Backman JT.
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):44-51. PubMed ID: 16867170
    [Abstract] [Full Text] [Related]

  • 10. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
    Tachibana S, Fujimaki Y, Yokoyama H, Okazaki O, Sudo K.
    Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
    [Abstract] [Full Text] [Related]

  • 11. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.
    Wen X, Wang JS, Backman JT, Laitila J, Neuvonen PJ.
    Drug Metab Dispos; 2002 Jun; 30(6):631-5. PubMed ID: 12019187
    [Abstract] [Full Text] [Related]

  • 12. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
    Wang JS, DeVane CL.
    Drug Metab Dispos; 2003 Jun; 31(6):742-7. PubMed ID: 12756206
    [Abstract] [Full Text] [Related]

  • 13. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
    Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, Robinson WT.
    Drug Metab Dispos; 1999 Mar; 27(3):410-6. PubMed ID: 10064574
    [Abstract] [Full Text] [Related]

  • 14. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
    Karam WG, Goldstein JA, Lasker JM, Ghanayem BI.
    Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
    [Abstract] [Full Text] [Related]

  • 15. Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes.
    Kim KA, Park JY.
    Drug Metab Dispos; 2003 Sep; 31(9):1090-2. PubMed ID: 12920163
    [Abstract] [Full Text] [Related]

  • 16. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes.
    Fang J, McKay G, Song J, Remillrd A, Li X, Midha K.
    Drug Metab Dispos; 2001 Dec; 29(12):1638-43. PubMed ID: 11717183
    [Abstract] [Full Text] [Related]

  • 17. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.
    Desta Z, Soukhova N, Mahal SK, Flockhart DA.
    Drug Metab Dispos; 2000 Jul; 28(7):789-800. PubMed ID: 10859153
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
    Miyazawa M, Shindo M, Shimada T.
    Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.